Rabbit Anti-Human VEGFR-2/KDR
Slide this table
| Cat-Nr. | 102-PA18S |
| Size | 100 µg |
| Price | 175 € |
| Category | Polyclonal Antibody |
| Clone Nr. | Rabbit IgG |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
| Preparation | Produced from sera of rabbits immunised with highly pure recombinant human soluble extracellular domain of KDR (110 kDa) as the immunizing antigen. Anti-human VEGFR-2/KDR was purified by affinity chromatography with immobilized protein A. The antibody is identical with the former described antibody r212 (see Lit.) |
| Antigen | Recombinant human KDR (D1-7) (RT #S01-001) |
| Application | WB, E, IP |
| Synonyms | vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor |
| Description | VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. |
| Uniprot ID | P35968 |
| Protein RefSeq | NP_002244.1 |
| mRNA RefSeq | NM_002253.2 |
Figures
IHC with cryo sections of human spleen.
The experiment was performed by Prof. Dr. Birte Steiniger, Institute of Anatomy and Cell Biology, University Marburg, Germany
Western Blot Analysis of anti-human VEGFR-2/KDR. Samples were loaded in 10% SDS-polyacrylamide gel under reducing conditions.
FACS analysis with primary human umbilical vein endothelial cells (HUVEC).
FACS analysis with primary human dermal lymphatic endothelial cells (HDLEC).
Reference
- The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. S. Dedieu et al., BMC Med. 2010; 8: 19.
All prices plus VAT + possible delivery charges